Abstract
Lung cancer is the leading cause of cancer-related death in the United States. Emerging technologies for the treatment of early-stage non-small cell lung cancer are currently focused on less invasive approaches to obtaining local tumor control, including minimally invasive and less radical resections, as well as image-guided ablative therapies. Targeted chemotherapeutic agents represent the newest area of treatment for advanced non-small cell lung cancer. These novel agents capitalize on our increased understanding of the diverse biology of the disease. Each of these advanced modalities works best for only a small subset of the population with lung cancer, and efficacious use is highly dependent on appropriate patient selection.
Original language | English (US) |
---|---|
Pages (from-to) | 175-185 |
Number of pages | 11 |
Journal | Journal of thoracic imaging |
Volume | 26 |
Issue number | 2 |
DOIs | |
State | Published - May 2011 |
Keywords
- Non-small cell lung cancer
- bevacizumab
- epidermal growth factor receptor
- pemetrexed
- percutaneous ablative therapy
- stereotactic body radiation therapy
- sublobar resection
- targeted therapies
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Pulmonary and Respiratory Medicine